Quantitative Analysis of Survivin Protein Expression and Its Therapeutic Depletion by an Antisense Oligonucleotide in Human Lung Tumors by Olsen, A, Davies, J, Medley, L, Breen, D, Talbot, D, McHugh, P

Diagnostic bronchoscopy: a window of opportunity for timely biomarker driven therapy in non-small cell lung cancer (NSCLC) by Medley, L, West, S, Davies, J, Clelland, C, Olsen, A, McHugh, P, Talbot, D

The potential for tailored therapy based on molecular characteristics of endobronchial tumour sampling at diagnosis by Medley, L, West, S, Davies, J, Clelland, C, Olsen, A, McHugh, P, Talbot, D

Chemotherapy does not increase the risk of pleural infection in patients managed with an indwelling pleural catheter for malignant pleural effusion by Morel, A, Mishra, E, Medley, L, Rahman, N, Wrightson, J, Talbot, D, Davies, R

Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion by Morel, A, Mishra, E, Medley, L, Rahman, N, Wrightson, J, Talbot, D, Davies, R

Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. by Morel, A, Mishra, E, Medley, L, Rahman, N, Wrightson, J, Talbot, D, Davies, R

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. by Medley, L, Morel, A, Farrugia, D, Reed, N, Hayward, N, Davies, J, Kirichek, O, Thakker, R, Talbot, D

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours by Medley, L, Morel, A, Farrugia, D, Reed, N, Hayward, N, Davies, J, Kirichek, O, Thakker, R, Talbot, D

PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR by Murphy, F, Church, D, Medley, L, Davies, J, Breen, D, Clelland, C, Mackintosh, D, Mugalaasi, H, Butler, R, Talbot, D

Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study by Nicholson, BD, Oke, J, Virdee, PS, Harris, DA, O'Doherty, C, Park, JES, Hamady, Z, Sehgal, V, Millar, A, Medley, L, Tonner, S, Vargova, M, Engonidou, L, Riahi, K, Luan, Y, Hiom, S, Kumar, H, Nandani, H, Kurtzman, KN, Yu, L-M, Freestone, C, Pearson, S, Hobbs, FR, Perera, R, Middleton, MR

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial by Iveson, T, Kerr, R, Saunders, M, Cassidy, J, Hollander, N, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H, Paul, J